Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rani Therapeutics Holdings, Inc. (RANI : NSDQ)

• Company Description    Rani Therapeutics Holdings Inc. is a clinical stage biotherapeutics company. It focused on advancing technologies to enable the development of orally administered biologics. Rani Therapeutics Holdings Inc. is based in SAN JOSE, Calif. Number of Employees: 106

• Price / Volume Information    Yesterday's Closing Price: $0.66 Daily Weekly Monthly 20 Day Moving Average: 296,447 shares Shares Outstanding: 57.48 (millions) Market Capitalization: $37.96 (millions) Beta: -0.02 52 Week High: $4.19 52 Week Low: $0.46 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.81% 13.39% 12 Week -43.56% -52.53% Year To Date -51.80% -54.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2051 RINGWOOD AVENUE - SAN JOSE,CA 95131 USA ph: 408-457-3700 fax: - investors@ranitherapeutics.com http://www.ranitherapeutics.com

• General Corporate Information    Officers Talat Imran - Chief Executive Officer and Director Mir Imran - Chairman Svai Sanford - Chief Financial Officer Dennis Ausiello - Director Jean-Luc Butel - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 753018100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 57.48 Most Recent Split Date: (:1) Beta: -0.02 Market Capitalization: $37.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 24.14% vs. Previous Quarter: 18.52% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -83.27% ROE 06/30/25 - - 03/31/25 - -1,258.76 12/31/24 - -409.05 ROA 06/30/25 - - 03/31/25 - -80.52 12/31/24 - -67.68 Current Ratio 06/30/25 - - 03/31/25 - 0.88 12/31/24 - 1.50 Quick Ratio 06/30/25 - - 03/31/25 - 0.88 12/31/24 - 1.50 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -4,545.25 12/31/24 - -5,504.28 Book Value 06/30/25 - - 03/31/25 - -0.09 12/31/24 - 0.06 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 2.75 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 73.35

Powered by Zacks Investment Research ©